期刊文献+

宫颈癌化疗前后多药耐药基因产物表达的比较研究 被引量:7

Studies of Multdrug Resistance Gene Expression in Cervical Carcinoma Before and After Chemotherapy
下载PDF
导出
摘要 目的 :探讨宫颈癌化疗前后癌组织中P 糖蛋白 (P gp)、胎盘型谷胱甘肽S 转移酶 (GST Л )及DNA拓扑酶Ⅱ (TopoⅡ )的表达及临床意义。方法 :用免疫组化S P法检测了 5 6例宫颈癌。结果 :化疗后宫颈癌组织中GST Л、P gp的表达率分别由化疗前的 5 7 14 %升高到 92 86 % ,2 8 5 7%升高到82 14 % ,而TopoⅡ在化疗后表达强度降低。化疗前GST Л的阳性率与化疗后癌组织的化疗反应呈负相关 (P <0 0 1)。结论 :GST Л、P gp及TopoⅡ的表达与宫颈癌多药耐药性相关 ,GST Л的高表达可能在宫颈癌耐药中起主导作用 ,检测宫颈癌组织中GST Л、P Objective To approach GST Л,P gp and TopoⅡ expression and their clinical significance in cervical carcinoma . Methods The specimens of 56 cases of cervical carcinoma before and after chemotherapy were examined with S P immunohistochemistry.Results The total positive expression rates of GST Л and P gp in cervical carcinoma after chemotherapy were 92 86% and 82 14%,it was significantly higher than that of pretreatment (57 14%,28 57%).The staining reaction of TopoⅡ was decreased in cervical carcinoma after chemotherapy.Expression of GST Л before and after chemotherapy was negatively relative to chemotherapeutic response( P <0 01).Conclusions GST Л,P gp and TopoⅡ expression in cervical carcinoma are related to multidrug resistance.Overexpression of GST Л may be the most important factor.To detect GST Л,P gp and TopoⅡin carcinomous tissue is important for evaluating chemotherapeutic effect.
出处 《肿瘤防治杂志》 2002年第4期398-399,共2页 China Journal of Cancer Prevention and Treatment
基金 云南省卫生厅青年基金资助项目 (980 0 6)
关键词 宫颈癌 化疗 多药耐药基因 表达 比较研究 cervical neoplasms gene expression drug tolerance/genetics immuneohistochemistry
  • 相关文献

参考文献2

二级参考文献8

  • 1Hamada SI,Kamada M,Furumoto H,et al.Expression of glutathione S-transferase-πin human ovarian cancer as an indicator of resistance to chemotherapy[].Gynecologic Oncology.1994
  • 2Green JA,Robertson LJ,Clark AH.Glutathione S-transferase expression in benign and malignant ovarian tumours[].British Journal of Cancer.1993
  • 3Rubin SC,Finstad CL,Hoskins WJ,et al.Expression of P-glycoprotein in epithelial ovarian: evaluation as a marker of multidrug resistance[].American Journal of Obstetrics and Gynecology.1990
  • 4Van der zee A,Hollema H,Suurmeijer A JH.Value of P-glycoprotein,glutathione S-transferase pi, erbB-2, and p53 as prognostic factors in ovarian carcinomas[].Journal of Clinical Oncology.1995
  • 5Katagiri A,Tomita Y,Nishiyama T,et al.Immunohistochmical detection of P-glycoprotein and GST-pi in testis cancer[].British Journal of Cancer.1993
  • 6Van der zee A,Ommen BV,Meijer C.Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyctophosphamide chemotherapy[].British Journal of Cancer.1992
  • 7Perez RP,Hamilton TC,Ozols RF,et al.Mechanisms and modulation of resistance to chemotherapy in ovarian cancer[].Cancer.1993
  • 8Ferry DR,Kerr DJ.Multidrug resistance in cancer[].British Medical Journal.1994

共引文献14

同被引文献85

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部